There needs to be a national dialogue on how can we reach a point where our dollars are used wisely, patients get what they need, and we all get the innovation that we want, said Robert Dubois, MD, PhD, chief science officer and executive vice president, National Pharmaceutical Council.
There needs to be a national dialogue on how can we reach a point where our dollars are used wisely, patients get what they need, and we all get the innovation that we want, said Dr Robert Dubois, MD, PhD, chief science officer and executive vice president, National Pharmaceutical Council.
Transcript (slightly modified)
How will Going Below the Surface address the question of how well do we spend when it comes to healthcare? How will this help give an understanding to what’s driving healthcare spending?
We believe there is a national dialogue that needs to be occur, and a national dialogue that’s quite different than the 1 we’ve had in the past. For decades, we’ve had finger pointing exercises: “This is too expensive, this is causing the rise in expenditures, and if we’d only solve this problem, we’d have it resolved.”
The reality is, it’s an extensive and a difficult dialogue. Going Below the Surface initiative is really to do that, and to being to have those really tough questions talked about, looking at the costs, not just of drugs or hospitals, but also of devices and seeing specialists rather than primary care doctors or the lack of focus on social determinants. It’s really having that broad dialogue, and to not just look at the costs and pointing those fingers, but rather looking at the costs and benefits, and trying to very carefully say: “What would be best? How can we reach a point where our dollars are used wisely, patients get what they need, and we all get the innovation that we want.”
The Going Below the Surface initiative is really an opportunity to talk and reach that end of the journey.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More